FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
18/03/2024
Voltar para busca
Dado oficial do USPTO
SECARNA
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: VerbalEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
34
Atualização mais recente
18/03/2024
Classificação
Registrada
Tipo de marca
Verbal
Classes Nice
42, 45
Data de depósito
19/01/2022
Data de registro
21/11/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
21/11/2023
Última transação
21/11/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
4
Tipo de titular
28
Localização do titular
DE
Examinador
HAYS, CANDACE
Unidade examinadora
M10
Localização atual
PUBLICATION AND ISSUE SECTION
Titulares e representantes
Titulares
Secarna Pharmaceuticals GmbH & Co. KG
Representantes
B. Anna McCoy McCoy Russell LLP
Classificação técnica
Classes Nice
Classe 42Classe 45
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 42
Scientific research services in the field of biochemistryexcept for the field of cell culture products; Scientific research services in the field of nucleic acids and bioinformaticsin particular molecular- biological work methodsespecially antisense technology; design of pharmaceutical active ingredients by means of the aforesaid methods and technologiesalso using techniques of bioinformatics; development of pharmaceutical products by means of the aforesaid methods and technologiesalso using techniques of bioinformaticsincluding carrying out associated test and diagnostic methods; information technology (IT) consultancy services for the pharmaceutical and biotechnological industry; consultancy for others in the field of biochemistry and nucleic acids and bioinformaticsincluding antisense technologywith respect to the development of pharmaceutical products; safety and efficacy testing consultancy for others with respect to the evaluation of safety and efficacy of pharmaceutics; evaluation of pharmaceutical products with respect to their safety and efficacy to assure compliance with industry standards
Classe 45
Granting of licenses to others in industrial property rights in the field of scientific research services in the field of biochemistryexcept for the field of cell culture productsscientific research services in the field of nucleic acids and bioinformaticsin particular molecular-biological work methodsespecially antisense technologydesign of pharmaceutical active ingredients by means of the aforesaid methods and technologiesalso using techniques of bioinformatics and development of pharmaceutical products by means of the aforesaid methods and technologiesalso using techniques of bioinformaticsincluding carrying out associated test and diagnostic methods
Publicações
Histórico de despachos e eventos da marca no USPTO.
34 publicações encontradas
FICS
FINAL DISPOSITION NOTICE SENT TO IB
22/02/2024
FIMP
FINAL DISPOSITION PROCESSED
22/02/2024
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
21/02/2024
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
21/11/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
21/11/2023
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
12/11/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
25/10/2023
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
25/10/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
05/09/2023
PUBO
PUBLISHED FOR OPPOSITION
05/09/2023
GPNX
NOTIFICATION PROCESSED BY IB
04/09/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
16/08/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
16/08/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
16/08/2023
PBCR
WITHDRAWN FROM PUB - OG REVIEW QUERY
25/07/2023
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
10/07/2023
XAEC
EXAMINER'S AMENDMENT ENTERED
14/06/2023
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
14/06/2023
GNEA
EXAMINERS AMENDMENT E-MAILED
14/06/2023
CNEA
EXAMINERS AMENDMENT -WRITTEN
14/06/2023
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
09/05/2023
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
08/05/2023
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
08/05/2023
RFNT
REFUSAL PROCESSED BY IB
07/02/2023
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
17/01/2023
RFRR
REFUSAL PROCESSED BY MPU
17/01/2023
DOCK
ASSIGNED TO EXAMINER
17/01/2023
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
07/11/2022
CNRT
NON-FINAL ACTION WRITTEN
06/11/2022
DOCK
ASSIGNED TO EXAMINER
28/10/2022
MAFR
APPLICATION FILING RECEIPT MAILED
24/05/2022
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
20/05/2022
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
19/05/2022
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace SECARNA ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.